IBDEI1AH ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22836,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,22837,0)
 ;;=238.4^^125^1397^109
 ;;^UTILITY(U,$J,358.3,22837,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22837,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,22837,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,22837,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,22838,0)
 ;;=V58.61^^125^1397^126
 ;;^UTILITY(U,$J,358.3,22838,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22838,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,22838,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,22838,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,22839,0)
 ;;=282.49^^125^1397^117
 ;;^UTILITY(U,$J,358.3,22839,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22839,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,22839,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,22839,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,22840,0)
 ;;=289.89^^125^1397^15
 ;;^UTILITY(U,$J,358.3,22840,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22840,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,22840,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,22840,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,22841,0)
 ;;=238.79^^125^1397^88
 ;;^UTILITY(U,$J,358.3,22841,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22841,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,22841,1,5,0)
 ;;=5^Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,22841,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,22842,0)
 ;;=287.30^^125^1397^110
 ;;^UTILITY(U,$J,358.3,22842,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22842,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,22842,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,22842,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,22843,0)
 ;;=288.09^^125^1397^8
 ;;^UTILITY(U,$J,358.3,22843,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22843,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,22843,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,22843,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,22844,0)
 ;;=V10.21^^125^1397^61
 ;;^UTILITY(U,$J,358.3,22844,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22844,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,22844,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,22844,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,22845,0)
 ;;=284.2^^125^1397^106
 ;;^UTILITY(U,$J,358.3,22845,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22845,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,22845,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,22845,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,22846,0)
 ;;=202.40^^125^1397^76
 ;;^UTILITY(U,$J,358.3,22846,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22846,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,22846,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,22846,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,22847,0)
 ;;=287.49^^125^1397^118
 ;;^UTILITY(U,$J,358.3,22847,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22847,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,22847,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,22847,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,22848,0)
 ;;=180.9^^125^1397^29
 ;;^UTILITY(U,$J,358.3,22848,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22848,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,22848,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,22848,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,22849,0)
 ;;=203.02^^125^1397^104
 ;;^UTILITY(U,$J,358.3,22849,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22849,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,22849,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,22849,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,22850,0)
 ;;=204.02^^125^1397^2
 ;;
 ;;$END ROU IBDEI1AH
